Weight Regain After Stopping a GLP-1

If you stop a GLP-1, regaining some weight is common, and the published data say so plainly: in the STEP 1 extension, participants regained about two thirds of their lost weight roughly a year after stopping semaglutide. The main driver is simple. The drug's appetite suppression fades, hunger and food noise return, and intake climbs back up. This is not a reason to fear stopping, but it is a reason to plan for it, and the muscle you preserved is your best insurance.

This article covers why regain happens, what the trials actually show, and how preserved muscle and the habits you built blunt the rebound. It applies to Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). This is general education, not medical advice. Whether and how to stop a GLP-1 is an individual decision to make with your prescriber.

What the data actually show

Let us start with the numbers, attributed precisely, because vague fears are less useful than the real figure.

The clearest evidence comes from the STEP 1 extension (Diabetes, Obesity and Metabolism, 2022). In the original STEP 1 trial, the semaglutide group lost a mean of about 17.3 percent of body weight over 68 weeks. Then the drug stopped. Over the following year off treatment (weeks 68 to 120), that group regained a mean of about 11.6 percentage points of body weight. In plain terms: approximately two thirds of the lost weight came back within a year of stopping.

A few details matter for an honest read. At week 120, the net weight change from baseline was still about minus 5.6 percent, so participants did not bounce all the way back to where they started; they held roughly a third of the loss on average. The share who still had at least 5 percent weight loss dropped from about 86 percent at peak to about 48 percent a year after stopping. And the cardiometabolic improvements (blood pressure, lipids, glycemia) largely reverted toward baseline as well.

The flip side of the same coin is what happens when you stay on. SURMOUNT-4 found that people who continued tirzepatide kept most of their loss, while those switched to placebo regained meaningfully. Taken together, the picture is consistent: these drugs behave like ongoing chronic-condition medications, where the effect persists while you take them and fades when you stop. The decision to continue, lower the dose, or taper belongs with your prescriber, and the trade-offs are covered in GLP-1 maintenance after goal weight.

Why weight comes back

Regain after stopping is not a willpower failure. It is biology doing exactly what it is built to do.

The primary mechanism is appetite. The medication does a lot of heavy lifting on hunger and food noise. When it leaves your system, that suppression fades, and the appetite you had before treatment returns. The old environment and the old habits are still there, and now there is no pharmacological brake. Eating drifts back up, often without a conscious decision.

There is a set-point angle worth understanding, too. The "set point" theory holds that your body defends a weight range through appetite and metabolism, and there is reasonable evidence GLP-1s lower that defended range while you take them. Stopping appears to let the defended range drift back up, which is part of why regain is so common. Whether habits and muscle can help "hold" a lower set point after stopping is unsettled, and we explore it in GLP-1s and your body's set point.

One timing detail softens the cliff. The drug does not vanish the day you take your last dose. Semaglutide has a half-life of roughly seven days and tirzepatide roughly five, so appetite suppression fades gradually over several weeks rather than switching off overnight. That gradual fade is a runway: a window where hunger is climbing but not yet at full strength, which is the ideal time to lock in the habits that hold your result.

Some people and their prescribers use that biology deliberately, tapering the dose down rather than stopping abruptly, or moving to a lower maintenance dose instead of coming off entirely. The idea is to let appetite return slowly enough that habits can keep pace, rather than facing a sudden surge of hunger all at once. Whether a taper, a lower maintenance dose, or a clean stop fits you is a clinical decision, not a self-directed one, and it depends on your health and goals. The point is that "stopping" is not a single switch; it is a transition you can plan for.

Muscle is your insurance against regain

Here is the muscle-first thesis, and it is the part most regain advice misses entirely: the muscle you kept on the way down is metabolic insurance against gaining it back.

Muscle is metabolically active tissue. At rest it burns meaningfully more energy than fat does, on the order of roughly 13 kcal per kilogram per day for muscle versus about 4.5 for fat (these are approximate figures, and the popular "one pound of muscle burns 50 calories a day" claim is an overestimate). The practical consequence is that more lean mass means a higher resting metabolic rate, which means more calorie headroom before returning appetite tips you into a surplus.

This is why losing muscle during weight loss is a double penalty. Research suggests roughly 25 to 40 percent of total weight lost on a GLP-1 can come from lean mass (which includes water and organ mass, not only skeletal muscle), based on body-composition substudies of the STEP and SURMOUNT trials. If a big share of your loss was muscle, you shrank your own metabolic engine, and when appetite returns after stopping, that smaller engine makes regain easier. Conversely, the more muscle you protected, the more metabolic margin you carry into the high-risk window.

To be precise about the strength of this claim: the link from preserved muscle to less regain is mechanistically reasonable rather than proven by a dedicated trial. But it points the same direction as everything else, and protecting muscle costs you nothing and pays off in function and strength regardless. The full case is in keeping your muscle after stopping a GLP-1.

The habits that carry the result

If muscle is the insurance, habits are the premium you keep paying. The same three levers that protected muscle on the drug are what hold your result after it.

Keep protein high. As appetite returns, it becomes easier to hit your protein target, not harder, so spend that returning appetite deliberately. The 2025 joint advisory from the Obesity Medicine Association, The Obesity Society, the American Society for Nutrition, and the American College of Lifestyle Medicine recommends roughly 1.2 to 1.6 g/kg of body weight per day during active weight loss, and keeping protein in or near that range as you transition biases any regained weight toward muscle rather than fat. The details are in how much protein on a GLP-1.

Keep lifting. Resistance training is the signal that tells your body to hold and build muscle, and it matters more after stopping, not less, because the drug is no longer doing the appetite work for you. Meta-analytic evidence suggests resistance training offsets the large majority of the lean-mass loss that dieting alone causes. Two to four sessions a week with progressive overload is enough for most people. See resistance training on a GLP-1.

Keep tracking. The most common post-stopping mistake is to put the scale and the app in a drawer at goal weight, then notice regain only when clothes stop fitting, which is months too late to fix cheaply. Tracking body composition through the taper catches drift while it is still a small correction.

Catch regain early, when it is small

The window right after stopping is the single highest-value time to keep measuring, and it is exactly when most people quit. A flat or slightly rising scale in this phase is ambiguous on its own: if you are training and eating protein, some of that returning weight is muscle and glycogen, which is the result you want. Without a body-composition read, you cannot tell good regain from fat creep, so you risk either panicking over normal muscle gain or ignoring real fat regain until it snowballs.

This is the precise window Myo is built for. It keeps charting your lean mass, fat mass, protein, and resistance sessions right through and after your taper, so you can watch muscle hold and fat stay off during the high-risk window most people stop measuring. If fat starts creeping up while lean mass holds, you see it early enough to adjust food or training rather than discovering it on a scale weeks later, when the correction is much larger. Myo is a tracking and education tool, not medical advice, and it is not affiliated with any GLP-1 maker.

The bottom line

Some regain after stopping a GLP-1 is common, and the STEP 1 extension puts a real number on it: roughly two thirds of lost weight back within a year, on average, when there is no maintenance plan. That is a reason to plan, not to panic. Appetite returns because the drug fades; the question is whether your habits and your muscle are ready to take over.

Protect muscle on the way down so you carry metabolic margin into the rebound window. Keep protein high and keep lifting as appetite returns, so regained weight goes toward muscle rather than fat. And keep tracking body composition through the taper, because catching drift early is the difference between a small correction and a big one. Do those three things and you give yourself the best odds of keeping the body, and the strength, you worked to build.

References

Weight regain after stopping semaglutide (~11.6 percentage points regained, about two thirds of lost weight, net ~5.6% loss at week 120; ~48% retained 5% loss): STEP 1 extension, Diabetes, Obesity and Metabolism 2022, PubMed 35441470 / PMC9542252.

Continued treatment maintains weight loss; withdrawal associated with regain: SURMOUNT-4, PubMed 38078870.

Lean-mass share of weight lost on GLP-1s (~25-40%): SURMOUNT-1 body-composition substudy (DOM 2025, doi:10.1111/dom.16275); STEP 1 and SUSTAIN 8 DXA analyses.

Protein target during weight loss (~1.2-1.6 g/kg/day): 2025 joint advisory from OMA, TOS, ASN, and ACLM, American Journal of Clinical Nutrition (PMC12264624).

Resistance training preserves lean mass in caloric restriction: PMC5946208; PMC12264624 advisory.

Muscle vs fat resting metabolic rate (~13 vs ~4.5 kcal/kg/day; "1 lb muscle = 50 cal" is an overestimate): ACE Fitness.

GLP-1 pharmacokinetics and half-life (semaglutide ~7 days, tirzepatide ~5 days): PNAS 10.1073/pnas.2415815121.